APA

Wuerstlein R., Sotlar K., Gluz O., Otremba B., von Schumann R., Witzel I., Schindlbeck C., Janni W., Schem C., Bauerfeind I., Hasmueller S., Tesch H., Paulenz A., Ghali N., Orujov E., Kates R. E., Cowens W., Hornberger J., Pelz E. & Harbeck N. (20170911). The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. : Current medical research and opinion.

Chicago

Wuerstlein R, Sotlar K, Gluz O, Otremba B, von Schumann R, Witzel I, Schindlbeck C, Janni W, Schem C, Bauerfeind I, Hasmueller S, Tesch H, Paulenz A, Ghali N, Orujov E, Kates R E, Cowens W, Hornberger J, Pelz E and Harbeck N. 20170911. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. : Current medical research and opinion.

Harvard

Wuerstlein R., Sotlar K., Gluz O., Otremba B., von Schumann R., Witzel I., Schindlbeck C., Janni W., Schem C., Bauerfeind I., Hasmueller S., Tesch H., Paulenz A., Ghali N., Orujov E., Kates R. E., Cowens W., Hornberger J., Pelz E. and Harbeck N. (20170911). The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. : Current medical research and opinion.

MLA

Wuerstlein R, Sotlar K, Gluz O, Otremba B, von Schumann R, Witzel I, Schindlbeck C, Janni W, Schem C, Bauerfeind I, Hasmueller S, Tesch H, Paulenz A, Ghali N, Orujov E, Kates R E, Cowens W, Hornberger J, Pelz E and Harbeck N. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. : Current medical research and opinion. 20170911.